scholarly journals Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients

Cureus ◽  
2019 ◽  
Author(s):  
Nuruna Lovely Nishuty ◽  
Md. Mehedi Hasan Khandoker ◽  
James Regun Karmoker ◽  
Sumiya Ferdous ◽  
Mohammad Shahriar ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Interleukin 6 ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Protein Levels ◽  
Reactive Protein ◽  
Drug Naïve

scholarly journals C-reactive protein and clinical subtypes of major depressive disorder at Zagazig University Hospitals

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Amany Elshabrawy Mohamed ◽  
Rafik Reda Abd El-Latif ◽  
Amira Mohamed Youssef ◽  
Abdallah Saad Ibrahim
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
C Reactive Protein ◽  
University Hospitals ◽  
Major Depressive ◽  
Reactive Protein

C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder

2016 ◽  
Vol 18 (1) ◽  
pp. 63-70 ◽  
Author(s):  
Hui Hua Chang ◽  
Tzu-Yun Wang ◽  
I Hui Lee ◽  
Sheng-Yu Lee ◽  
Kao Chin Chen ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Protein A ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Bipolar Ii Disorder ◽  
Reactive Protein ◽  
Bipolar Ii

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice

CNS Spectrums ◽  
2016 ◽  
Vol 22 (4) ◽  
pp. 342-347 ◽  
Author(s):  
Domenico De Berardis ◽  
Michele Fornaro ◽  
Laura Orsolini ◽  
Felice Iasevoli ◽  
Carmine Tomasetti ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Clinical Practice ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Real World ◽  
Level Variation ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Everyday Clinical Practice ◽  
Reactive Protein

ObjectiveAgomelatine is a newer antidepressant but, to date, no studies have been carried out investigating its effects on C-reactive protein (CRP) levels in major depressive disorder (MDD) before and after treatment. The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients.Methods30 adult outpatients (12 males, 18 females) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of MDD were recruited in “real-world,” everyday clinical practice and treated with a flexible dose of agomelatine for 12 weeks. The Hamilton Rating Scale for Depression (HAM-D) and the Snaith-Hamilton Pleasure Scale (SHAPS) were used to evaluate depressive symptoms and anhedonia, respectively. Moreover, serum CRP was measured at baseline and after 12 weeks of treatment.ResultsAgomelatine was effective in the treatment of MDD, with a significant reduction in HAM-D and SHAPS scores from baseline to endpoint. CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose.ConclusionsAgomelatine’s antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. Moreover, more prominent CRP level variation was associated with more severe depressive symptoms at baseline.

Sign in / Sign up

Export Citation Format

Share Document